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Electronically Monitored Medication Adherence Predicts Hospitalization in Heart
Failure Patients
Abstract
Background: Hospitalization contributes enormously to health care costs associated with heart failure.
Many investigators have attempted to predict hospitalization in these patients. None of these models has
been highly effective in prediction, suggesting that important risk factors remain unidentified.
Purpose: To assess prospectively collected medication adherence, objectively measured by the
Medication Event Monitoring System, as a predictor of hospitalization in heart failure patients.
Materials and methods: We used recently developed adaptive modeling methods to describe patterns of
medication adherence in a sample of heart failure patients, and tested the hypothesis that poor
medication adherence as determined by adaptive methods was a significant predictor of hospitalization
within 6 months.
Results: Medication adherence was the best predictor of hospitalization. Besides two dimensions of poor
adherence (adherence pattern type and low percentage of prescribed doses taken), four other single
factors predicted hospitalization: low hemoglobin, depressed ejection fraction, New York Heart
Association class IV, and 12 or more medications taken daily. Seven interactions increased the predictive
capability of the model: 1) pattern of poor adherence type and lower score on the Letter–Number
Sequencing test, a measure of short-term memory; 2) higher number of comorbid conditions and higher
number of daily medications; 3) higher blood urea nitrogen and lower percentage of prescribed doses
taken; 4) lower hemoglobin and much worse perceived health compared to last year; 5) older age and
lower score on the Telephone Interview of Cognitive Status; 6) higher body mass index and lower
hemoglobin; and 7) lower ejection fraction and higher fatigue. Patients with none of these seven
interactions had a hospitalization rate of 9.7%. For those with five of these interaction risk factors, 100%
were hospitalized. The C-index (the area under the receiver-operating characteristics [ROC] curve) for the
model based on the seven interactions was 0.83, indicating excellent discrimination.
Conclusion: Medication adherence adds important new information to the list of variables previously
shown to predict hospitalization in adults with heart failure.
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Background: Hospitalization contributes enormously to health care costs associated with heart
failure. Many investigators have attempted to predict hospitalization in these patients. None
of these models has been highly effective in prediction, suggesting that important risk factors
remain unidentified.
Purpose: To assess prospectively collected medication adherence, objectively measured by
the Medication Event Monitoring System, as a predictor of hospitalization in heart failure
patients.
Materials and methods: We used recently developed adaptive modeling methods to describe
patterns of medication adherence in a sample of heart failure patients, and tested the hypothesis
that poor medication adherence as determined by adaptive methods was a significant predictor
of hospitalization within 6 months.
Results: Medication adherence was the best predictor of hospitalization. Besides two
dimensions of poor adherence (adherence pattern type and low percentage of prescribed doses
taken), four other single factors predicted hospitalization: low hemoglobin, depressed ejection
fraction, New York Heart Association class IV, and 12 or more medications taken daily. Seven
interactions increased the predictive capability of the model: 1) pattern of poor adherence type
and lower score on the Letter–Number Sequencing test, a measure of short-term memory;
2) higher number of comorbid conditions and higher number of daily medications; 3) higher
blood urea nitrogen and lower percentage of prescribed doses taken; 4) lower hemoglobin
and much worse perceived health compared to last year; 5) older age and lower score on the
Telephone Interview of Cognitive Status; 6) higher body mass index and lower hemoglobin; and
7) lower ejection fraction and higher fatigue. Patients with none of these seven interactions had
a hospitalization rate of 9.7%. For those with five of these interaction risk factors, 100% were
hospitalized. The C-index (the area under the receiver-operating characteristics [ROC] curve)
for the model based on the seven interactions was 0.83, indicating excellent discrimination.
Conclusion: Medication adherence adds important new information to the list of variables
previously shown to predict hospitalization in adults with heart failure.
Keywords: heart failure, outcomes, hospitalization, patient compliance, medication
adherence, self-care
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Heart failure (HF) is the most prevalent and fastest-growing cardiovascular disease
worldwide.1 In the US among those 80 years of age and older, almost 12% of men
and women have HF, and the prevalence is projected to increase by 25% by 2030.1
Outcomes associated with HF include poor quality of life, high mortality, and frequent
hospitalizations that contribute enormously to health care costs.1
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In 2010, the Patient Protection and Affordable Care Act
was enacted to address the rising costs of health care in
the US.2 In 2012, value-based purchasing was introduced,
and hospitals began being financially spurred to produce
quality outcomes while reducing inappropriate spending.
Specifically, the Centers for Medicare and Medicaid Services
Readmissions Reduction Program financially penalizes
health care systems when the 30-day all-cause readmission rates for Medicare patients are higher than expected in
particular diagnostic categories. HF is one of the targeted
diagnoses, so efforts to identify modifiable factors predicting
HF hospitalizations are increasingly important.
Numerous investigators have attempted to predict hospitalization in adults with HF. In a recent review, Giamouzis
et al2 summarized risk factors for hospitalization as sociodemographic, clinical, blood and other test results, comorbidity
burden, and cardiovascular, noncardiovascular, quality of life,
psychosocial, and disease-management factors.2 Others have
attempted to synthesize these results by developing models
that can be used to predict hospitalization risk.3–9 None of
these models has been highly effective in prediction. The
C-index (the area under the receiver-operating characteristics
[ROC] curve) in the various studies ranged from 0.57 to 0.74,
suggesting that important risk factors remain unidentified.
The purpose of this study was to assess medication adherence as a predictor of hospitalization in adults with HF in
conjunction with other possible predictors.
Poor medication adherence is ubiquitous in chronically
ill patient populations.10 In a review of medication adherence
in HF, Wu et al11 noted that most investigators have found
nonadherence rates of 40%–60% of HF patients. Prior studies
have demonstrated that disease-management interventions
emphasizing evidence-based medications can decrease hospitalization rates,12 but few studies have addressed the risk
of hospitalization associated with medication nonadherence
in adults with HF. The few studies that have been done suggest that hospitalization rates are higher when medication
adherence is poor.13–16 These studies are limited, however, to
retrospective analyses of such electronic data as pharmacy
records.
In this study, we describe patterns of prospectively
collected, objectively measured medication adherence in a
sample of HF patients and test the hypothesis that medication adherence is a significant predictor of hospitalization
within 6 months. This approach addresses several important
gaps in the literature. First, collecting the data prospectively
negates the need for decision rules regarding the coding of
electronic data. Second, medication adherence was measured
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objectively with the Medication Event Monitoring System
(MEMS®) (Aardex; MW Healthcare, Richmond, VA, USA),
which is more accurate than self-reported medicationadherence data. Third, we used a statistical approach17,18 that
allowed us to utilize more fully these medication-adherence
data to characterize patients’ adherence patterns and to
identify adherence types with similar patterns, rather than
the usual approach of classifying adherence using an arbitrarily devised cutoff (usually .80%).19 Fourth, while these
methods have been used before to model MEMS adherence
data for human immunodeficiency virus-positive patients17,20
and for African-American patients with hypertension, 21
they have not been used before with adherence data from
HF patients.

Materials and methods
This was a planned analysis of longitudinal data from a prospective cohort study of a consecutive sample of 280 adults
with HF. Subjects were enrolled from three outpatient settings
in the northeastern US. Institutional review board approval
was obtained at each site, and all participants gave informed
consent. Data were collected between 2007 and 2009. A
detailed description of study methods has been published
previously.22
Patients with a confirmed diagnosis of chronic HF were
enrolled, regardless of etiology or ejection fraction. Inclusion
criteria addressed the ability to participate (eg, vision,
hearing, English literacy, and cognition).15 Cognition was
screened using the Telephone Interview of Cognitive Status
(TICS).23 Exclusion criteria were major depressive illness,
dementia, renal failure requiring dialysis, or a recent history
of serious drug or alcohol abuse.
Participants were followed for 6 months, with study visits
at baseline, 3, and 6 months. Data on self-care and cognition
were collected at each study visit. Most data were collected
during home visits by research assistants. Nurses abstracted
clinical information from medical records. For this analysis, we tested a wide range of demographic, social support,
clinical, self-care, symptom, and cognition variables, so as
to add to the knowledge of significant predictors previously
identified by others.2
The outcome variable of hospitalization was measured
using the electronic medical record at each participating institution. In addition, participants were telephoned
monthly and asked about hospitalizations (and also emergency department visits). Medical records were obtained if
the visit took place at a hospital outside of the home institution. In this analysis, all hospitalizations were analyzed,

Patient Preference and Adherence 2014:8

Dovepress

regardless of cause (not including emergency department
visits).

Measures
MEMS was used to measure medication adherence
objectively. Our methods for collecting MEMS data are
described in detail elsewhere;24 the MEMS data were used
differently in that study. In brief, using a microprocessor in
the cap, the MEMS® 6 device measures openings that are
presumed to be for the purpose of removing a pill to take it
orally. MEMS data were collected on one medication scheduled to be taken at fixed times. MEMS data were collected
over a 6-month interval and downloaded at 3 and 6 months.
Deviations in use, such as accidental openings, were noted in
study diaries and used to correct the time-stamped medication
events stored in the device before analysis. In this study, we
considered three aspects of adherence based on MEMS data:
adherence-pattern types, consistency of adherence patterns
with the prescribed rate, and the percentage of prescribed
doses taken (PDT). The medication controlled by MEMS did
not change for any of the patients during the study. For one
patient, the prescribed rate for the medication controlled by
MEMS changed during the study. The adherence pattern for
this patient was adjusted to account for this change.
Demographic variables, such as age, race, and sex were
collected by self-report. In addition to measuring education
as the number of years of formal schooling, the American
National Adult Reading Test (ANART) was administered as
a test of premorbid intellect.
Social support was measured in multiple ways. Marital
status was self-reported, as was living alone (yes/no) and the
overall quality of the support received defined as “emotional
support, information, material help, errands, etc,” with
responses ranging from 1 (poor) to 4 (very good). In addition, support from family, friends, and significant others
was assessed using the Multidimensional Scale of Perceived
Social Support (MSPSS).25 Responses range from 1 (very
strongly disagree) to 7 (very strongly agree), with higher
scores indicating higher perceptions of support.
Clinical variables included health-related factors, such as
exercise in the last week, which was assessed by self-report
with responses of 1 (none) to 4 (more than 3 hours). Body
mass index (BMI) was calculated from self-reported height
and measured body weight. Variables abstracted from the
medical record included months since diagnosed with HF,
most recent blood urea nitrogen (BUN), creatinine, hemoglobin (Hgb), serum sodium, and ejection fraction. The Charlson
Comorbidity Index26 was completed based on chart review.
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Any history of sleep apnea, atrial fibrillation, hypertension,
diabetes, cerebral disease, renal disease, anemia, or pulmonary hypertension was noted. Pulse and systolic and diastolic
blood pressure were measured during the enrollment visit.
Treatment quality was rated separately for systolic and diastolic HF, using those treatments advocated in HF clinical
guidelines (eg, angiotensin-converting enzyme-inhibitor use,
beta-blocker use) in place at the time.27
Self-care was measured with the Self-Care of HF Index
(SCHFI), which assesses self-care maintenance, management,
and confidence.28 Each scale is standardized to a score of 100,
with higher scores indicating better self-care. Knowledge of
HF was assessed using the Dutch HF Knowledge Scale29 with
15 dichotomously scored items; higher scores indicate higher
knowledge of HF treatment, HF symptoms, and symptom
recognition. The number of medications taken daily was
calculated based on a review of medication containers by
research assistants during home visits.
Symptoms measured by self-report included trouble
breathing or ankle swelling in the past month (yes/no), general health perceptions, rated 1 (excellent) to 5 (poor), and
health perception compared to 1 year prior, rated 1 (much
better now than 1 year ago) to 5 (much worse now than 1 year
ago). Information on functional class was gathered during
the home visit using a standardized interview. A single cardiologist scored New York Heart Association (NYHA) class
in every subject. Fatigue was measured using two items from
the Kansas City Cardiomyopathy Questionnaire.30 Each item
is scored 1 to 7; scores were reversed so that higher scores
indicated more fatigue. Sleepiness was assessed with the
Stanford Sleepiness Scale31 and the Epworth Sleepiness Scale
(ESS).32 ESS respondents rate the likelihood of falling asleep
in eight soporific situations on a scale ranging from 0 (never
dozing) to 3 (high chance of dozing). ESS scores are summed,
with higher scores indicating higher sleepiness or categorized
as sleepy ($11) or not sleepy (,11). Sleep quality was
assessed with the Pittsburgh Sleep Quality Index.33 A global
score (0–21 points) is obtained by summing the scale domain
scores. Higher scores indicate poorer sleep quality; a score
.5 is categorized as poor sleep. Depression was measured
using the Patient Health Questionnaire.34 Responses range
from 0 (not at all) to 3 (nearly every day), with higher scores
indicating more depression.
A neuropsychological test battery was administered
to measure simple attention (Psychomotor Vigilance Task
[PVT]), complex attention (Trail Making Test B), processing speed (Digit Symbol Substitution Test, Trail Making
Test A), working memory (Probed Recall Memory task),
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and short-term memory (Letter–Number Sequencing [LNS]
test).35 Transformed lapses .4.69 on the PVT were scored as
abnormal.36 Scores on each of the other tests were classified
based on age-based norms. In addition, the number of tests
scored as abnormal was used as a summary measure of
cognitive status. Anyone scoring .1.5 standard deviations
on two or more of the cognition tests was scored as having
cognitive decline. Efforts made to compensate for perceived
memory issues were measured and summarized in the Compensatory Activities Scale.

Data analysis
Other than standard analyses (eg, descriptive statistics),
analyses were conducted using the adaptive methods of
Knafl et al.17 These methods were used to characterize adherence patterns for individual patients over their 6 months in
the study, classify these patterns into adherence types, and
identify dichotomous risk factors, individually and in combination, for hospitalization.

Likelihood cross-validation
Adaptive methods use a K-fold likelihood cross-validation
(LCV) approach for evaluating and comparing alternative
models. Observations (eg, daily MEMS use) are randomly
partitioned into K disjoint subsets called folds. For a given
model, the likelihood for the data in each fold is computed
from model parameter values estimated using the data in the
other folds. These deleted fold likelihoods are normalized
by the sample size and multiplied up into the LCV score for
the model. Larger LCV scores indicate better models for
the data under analysis. LCV scores can be used for model
selection in any analysis context where parameter estimation
is based on maximizing a likelihood or any likelihood-like
function (eg, a quasi-likelihood). All analyses used 10-fold
LCV scores.
A larger LCV score does not necessarily mean the
model is preferable. If the smaller LCV score is not too
much smaller and the associated model has a simpler
structure (eg, using an untransformed predictor compared
to using the log transform of that predictor), then this model
is preferable as a parsimonious, competitive alternative.
LCV-ratio tests, analogous to likelihood-ratio tests, can
be used to assess whether a smaller LCV score is substantially (significantly or distinctly) smaller or not. These are
χ2-based tests and are expressed in terms of a cutoff for a
substantial percent decrease in the LCV score. The cutoff
changes with the sample size (for the formula, see [6] of
Knafl et al17).
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Individual adherence patterns
The study-participation period for each patient was subdivided into equally sized intervals of length at least 3 days
with no more than 100 intervals. Counts of MEMS cap
openings and opening rates per day per dose were computed
for each interval. These counts and rates were modeled using
Poisson regression models (as is appropriate for such data).
Both mean adherence and adherence variability based on
dispersion parameters37 were modeled as possibly nonlinear
functions of time during study participation. LCV scores
were based on extended quasi-likelihoods.
The predictors for the Poisson regression models
were power transforms of time with possibly fractional
(ie, noninteger) powers, and so these are called fractional polynomial models.38 An adaptive process was used to identify an
effective set of such power transforms. The adaptive process
starts from the constant model and systematically expands the
model, adding in power transforms of time to either the mean
adherence or dispersion component of the model, continuing
as long as the LCV score does not decrease by too much (as
determined by an expansion-stopping tolerance parameter).
The expanded model is then contracted by removing transforms of time or possibly the intercept term as long as the
LCV score does not decrease by too much (as determined by a
contraction-stopping tolerance parameter). The transforms of
the contracted model determine the adherence pattern underlying the data for how both mean adherence and adherence
variability change over time (examples are given in Figure 1,
as described in the “Results” section).
Since the prescribed rates were not the same for all
patients (ranging from one to three doses per day), adherence
patterns were normalized by the prescribed number of doses
to be comparable. The ideal adherence pattern is then the
one with constant mean adherence equal to 1 and constant
adherence variability equal to 0. A summary measure of how
consistent the observed adherence pattern is with this ideal
pattern is calculated for each patient as a percentage, and so
is called percentage consistency.

Adherence types
Mean adherence and adherence variability were estimated at
20 proportionally spaced times within each patient’s study
participation period (5%, 10%, . . . 100%). The 40 vectors
formed from these two types of estimates were clustered
into adherence types, ie, sets of patients with similar mean
adherence and adherence variability over time. A wide
variety of clustering procedures with varying numbers of
clusters were considered.17 These were compared using LCV
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Figure 1 Sample adherence patterns.
Notes: The raw data are plotted as diamonds. The middle curve is the estimated mean adherence over time while the other curves are unit error bands, ±1 estimated
standard deviation around mean adherence.

scores based on likelihoods for multivariate normal-mixture
models (as is appropriate for cluster analyses). The selected
clustering alternative was the one generating the best score
among those with at least 5% of the patients in each cluster
(to avoid sparse clusters). Plots of averages of mean adherence and adherence variability (ie, the centroids) were used
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in interpreting the clusters (see Figure 2, as described in the
“Results” section).

Identifying risk factors for hospitalization
Potential dichotomous risk factors were identified for
the dichotomous hospitalization-outcome variable.
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Figure 2 Plots of average mean adherence and of average adherence variability for patients in adherence types.

Most categorical predictors with more than two values were
reduced to dichotomous predictors expected to be risk factors.
For example, income level was reduced to not enough as the
risk factor versus enough or more than enough. Otherwise,
categorical predictors were represented by multiple dichotomous risk factors. For example, employment status was represented by being retired versus not and being unemployed
or disabled versus not. For each continuous and ordinal
predictor, its observed values were adaptively grouped into
two subsets of contiguous values. For each observed value
of the predictor (or a rounded value to reduce the number of
decimal digits) as a cutoff, LCV scores were computed for
the model based on the indicator for having values above or
below the cutoff. When a variable had missing values, these
were conservatively grouped with the non-risk-factor values
so that the effect of the associated risk factor held only for
patients with nonmissing values for the underlying variable.
The cutoff generating the best LCV score was chosen and the
risk factor defined in terms of values either above or below
the cutoff, depending on which of these choices had a positive effect on the outcome variable, ie, with odds ratio .1.
To avoid sparse cases, only those cutoffs were considered
for which at least 5% of the observations fell both above
and below the cutoff. When a standard cutoff existed for a
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predictor (eg, PVT .4.69), that categorization was considered as well.
To be consistent with the handling of other predictors,
adherence type was adaptively reduced to a dichotomous
risk factor of poor-adherence types versus better-adherence
types. Models of hospitalization were used for this purpose.
The decision regarding which adherence types to assign to
the two alternatives was made adaptively using LCV scores.
In contrast to the handling of values for continuous and
ordinal predictors, the alternate adherence types were not
considered to be ordered.
Data for patients with at least some MEMS data were
used to model hospitalization in terms of adherence and
other available risk factors, and so data for patients with no
MEMS data were missing for these analyses. Only outcome
means were adaptively modeled and not outcome dispersions,
using unit dispersions for all models (as for standard logistic
regression modeling). Bivariate models were generated for
all potential risk factors. Then, a multiple risk-factor model
was generated considering only the risk factors with a significant (P,0.05) bivariate effect. The adaptive modeling
process, as used for generating individual patient adherence
patterns in terms of the single predictor of time, was used
for this purpose. This multiple risk-factor model provides a
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parsimonious depiction of the combination of risk factors that
affect hospitalization. Next, interactions between the pooradherence type risk factor with each of the other available
risk factors were considered by starting with the model based
on these two risk factors and their interaction and adaptively
reducing that model to identify cases when an interaction
term remained in the model. A multiple risk-factor model
was generated considering these identified interaction effects
along with the noninteraction risk factors with significant
individual effects. Finally, an adaptive model was generated
considering this same set of risk factors as well as possible
interactions between any two of them to obtain a fuller assessment of interactions between risk factors.

A total of 280 HF patients participated in the study. Summary
statistics are presented in Tables 1–6 for available variables
within the six categories described earlier. For example,
patients were primarily male (64.3%), white (62.5%), and
retired (43.9%). Ages ranged from 24 to 89 years with a
mean of 62.0 (standard deviation =12.5) years, while education ranged from 8 to 29 years with mean of 13.9 (standard
deviation =2.9) years. Over the course of the 6-month study,
103 (36.8%) of the patients were hospitalized.

Individual patient adherence patterns
MEMS adherence data were available for 218 (77.9%)
patients. Of these patients, 79 (36.2%) were hospitalized
Table 1 Summary statistics for available demographic variables
Variable

Observed range

n (%)a

Employment
status

Retired
Unemployed or disabled
Employed (full or part time)
Male
Female
Do not have enough
Have enough or more
than enough
Government or none
Commercial or HMO
Non-white
White
24–89
0–49
8–29

123 (43.9)
79 (28.2)
78 (27.9)
180 (64.3)
100 (35.7)
45 (16.1)
235 (83.9)

Income

Insurance
Race
Age, years
ANART score
Years of
education

Variable

Observed range

n (%)a

Living alone

Yes
No
Single, divorced,
separated, or widowed
Married or partnered
Satisfactory to good
Very good
14–84

59 (21.1)
221 (78.9)
121 (43.2)

Marital status

Quality of
support
MSPSS score

Mean
(SD)

159 (56.8)
105 (37.5)
175 (62.5)
72.6 (11.5)

Note: aOut of 280 patients.
Abbreviations: SD, standard deviation; MSPSS, Multidimensional Scale of Perceived
Social Support.

Table 3 Summary statistics for available clinical variables

Results
Sample

Sex

Table 2 Summary statistics for available social support variables

Mean
(SD)

Observed
range

n (%)a

Exercise

None
Some
0.00–1.00

57 (20.4)
223 (79.6)

Adherence to treatment
guidelines
Body mass index
Blood urea nitrogen
Charlson total
Comorbidities
Creatinine
Diastolic blood pressure
Ejection fraction
Hemoglobin
Months since heart
failure diagnosis
Pulse
Serum sodium
Systolic blood pressure

155 (55.4)
125 (44.6)
105 (37.5)
175 (62.5)
62.0 (12.5)
29.8 (11.8)
13.9 (2.9)

Mean
(SD)

0.8 (0.2)

15.0–67.0
6–97
1–11
0–9
0.5–3.4
45–103
5–80
7.9–18.4
0–508

30.9 (7.9)
25.4 (15.1)
2.8 (1.7)
3.1 (2.1)
1.3 (0.6)
69.0 (11.2)
35.4 (17.0)
13.0 (1.8)
73.4 (71.1)

42–100
131–146
80–176

69.7 (11.4)
139.0 (4.0)
116.1 (18.4)

Note: aOut of 280 patients.
Abbreviation: SD, standard deviation.

Table 4 Summary statistics for available self-care variables
Variable

Observed
range

n (%)

MEMS data availablea

No
Yes
Poor
Better
2–3
1
7–15
42–100
32–92
29–100
1–25
0.1–93.9
5.8–100

62 (22.1)
218 (77.9)
63 (28.9)
155 (77.5)
133 (61.0)
85 (39.0)

Adherence typeb

Note: aOut of 280 patients.
Abbreviations: SD, standard deviation; HMO, health maintenance organization;
ANART, American National Adult Reading Test.
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Variable

Prescribed rate for medication
controlled by MEMSb
DHFKS score
SCHFI self-care confidence
SCHFI self-care maintenance
SCHFI self-care management
Total medications
Consistency, %
Prescribed doses taken, %

Mean
(SD)

11.7 (1.7)
75.8 (14.4)
66.8 (11.9)
67.4 (18.7)
9.9 (4.0)
47.6 (34.8)
71.1 (25.9)

Notes: aOut of 280 patients; bout of 218 patients with available MEMS data.
Abbreviations: SD, standard deviation; DHFKS, Dutch Heart Failure Knowledge
Scale; MEMS, Medication Event Monitoring System; SCHFI, Self-Care of Heart
Failure Index.
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Table 5 Summary statistics for available symptom variables
Variable

Observed range

n (%)a

General health
perception
Health compared to
a year ago

Poor
Fair to excellent
Much worse now
than a year ago
Not much worse
now than a year ago
Yes
No

37 (13.2)
243 (86.8)
24 (8.6)

IV
I–III
2–13
1–6
0–23
0–19
0–18

50 (17.9)
230 (82.1)

Trouble breathing or
ankle swelling within
past month
NYHA class
Fatigue
SSS score
ESS score
PSQI global score
PHQ total

Mean (SD)

256 (91.4)
125 (44.6)
155 (55.4)

6.5 (3.2)
2.3 (1.2)
7.0 (4.6)
7.2 (4.1)
4.4 (3.6)

Note: aOut of 280 patients.
Abbreviations: SD, standard deviation; ESS, Epworth Sleepiness Scale; NYHA,
New York Heart Association; PHQ, Patient Health Questionnaire; PSQI,
Pittsburgh Sleep Quality Index; SSS, Stanford Sleepiness Scale.

during the study. Hospitalization rates were not significantly
different for patients with no MEMS data versus some MEMS
data (χ2[1]=0.13, P=0.722).
Figure 1 contains plots of adherence patterns for seven
exemplar patients. The y-axis of these plots is openings
per day per dose with an ideal value of 1, while the x-axis
is cumulative days of study participation. The raw data
are plotted as diamonds. The middle curve is the estimated mean adherence over time, while the other curves
are unit error bands, ±1 estimated standard deviation (as
extended to account for nonlinear dispersion) around mean
adherence.
Patient 1 had mean adherence close to the prescribed
rate with small variability, which was 93.4% consistent with
Table 6 Summary statistics for available cognition variables
Variable

Observed range

Mean (SD)

CAS score
DSST score
LNS score
PMR score
PVT lapses
TICS score
TMTA score
TMTB score
Dimensions cognitively impaired

0–23
11–96
1–20
0–4
0–79
26–40
14–120
8–300
0–5

9.2 (4.4)
53.4 (17.5)
8.7 (3.5)
2.0 (1.2)
8.5 (13.1)
33.6 (3.1)
43.8 (22.3)
111.2 (59.1)
1.7 (1.0)

Abbreviations: SD, standard deviation; CAS, Compensatory Activities Score;
DSST, Digit Symbol Substitution Test; LNS, Letter–Number Sequencing;
PMR, Probed Memory Recall; PVT, Psychomotor Vigilance Task; TICS, Telephone
Interview for Cognitive Status; TMTA, Trail Making Test A; TMTB, Trail
Making Test B.
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adherence at the prescribed rate. Patient 2’s mean adherence
was close to the prescribed rate, with small variability up
to about 120 days of study participation. After that, mean
adherence decreased somewhat with increased variability
for 79.9% consistency with the prescribed rate. Patient 3
had deteriorating mean adherence from about the prescribed
rate to around half the prescribed rate, with low variability
and 61.7% consistency. Patient 4’s mean adherence was
close to the prescribed rate, with small variability up to
about 150 days of study participation, after which adherence
dropped to essentially zero for 40.0% consistency. Patient 5
had relatively consistent mean adherence at around half
the prescribed rate, with moderate variability and 15.5%
consistency. Patient 6’s mean adherence started at about
the prescribed rate and decreased to zero by about 90 days
of study participation, with variability decreasing for a
while and then increasing. After that, adherence remained
at zero. This pattern was only 1.0% consistent with prescribed adherence. In contrast, the PDT for this patient was
48.9%, suggesting that the patient was adherent at around
half the prescribed rate. The plot indicates that patient 6
was adherent around the prescribed rate for about half the
time and zero adherent the rest of the time, resulting in a
percentage PDT close to 50%, but never around 50% at
any time. In cases like this, percentage PDT provides a
misleading assessment of adherence, since it is based on
an assumption of constant adherence over time. Patient 7
had mean adherence starting around half the prescribed rate
and deteriorating quickly to nearly zero, with low variability
and 0.1% consistency.

Adherence types
Cluster analysis identified seven adherence types. Figure 2
contains plots of averages of mean adherence and of adherence variability for patients in the seven clusters. These plots
were used to generate the interpretations of the adherence
types given in Table 7. The clusters were numbered so that
averages of percentage consistency and percentage PDT
decreased. Consequently, cluster 1 corresponded to the
best adherence type, with mean adherence consistently
very close to the prescribed rate and adherence variability
consistently low. Cluster 7 corresponded to the worst adherence type, with mean adherence starting at about half the
prescribed rate and moderate adherence variability, then
deteriorating quickly to low, not too much above zero mean
adherence and adherence variability. The adherence patterns
of patients 1–7 were allocated to clusters 1–7, respectively.
The individual patterns of Figure 1 are only similar to the
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Table 7 Description of adherence types
Cluster

n

%

1
2
3
4
5

72
30
24
18
29

33.0
13.8
11.0
8.3
13.3

6
7
Total

29
16
218

13.3
7.3
100

Adherence types
Mean adherence

Adherence variability

High
High to moderately high
Moderately high to moderate
High to zero later
Below moderate to above
moderate and then to
below moderate
High to zero earlier
Moderate to low

Low
Low to high
Moderate
Moderate to zero
Moderate to moderately
high and then to
moderate
High to zero
Moderate to low

associated plots of Figure 2 since these latter plots are
based on averages.

Risk factors for hospitalization
The adaptively generated dichotomous risk factor based
on the seven adherence types for predicting hospitalization was the poor-adherence type, consisting of clusters 4, 6, and 7, versus better adherence, consisting of
clusters 1–3 and 5. Table 8 presents results for characterizing

Average %
consistency

Average % prescribed
doses taken

84.8
64.9
49.6
30.3
15.8

96.0
88.2
71.7
70.1
45.6

4.1
2.7

44.9
5.8

hospitalization, considering the variables of Tables 1–6.
Individual risk-factor analyses identified 21 significant
(P,0.05) risk factors for hospitalization: two demographic,
zero social support, seven clinical, five self-care, six
symptom, and one cognition. The cutoff for a substantial
percentage decrease in LCV scores for a sample of size 218
is 0.68%. The percentage decrease exceeded this cutoff for
16 (76.2%) of the 21 variables (LCV scores not reported),
indicating that LCV ratio tests are more conservative than

Table 8 Significant individual risk factors for hospitalization
Variable type

Variable

Risk factor

At-risk group, n (%)a

P-value

OR

95% CI

Demographic

Age, years
ANART score
–
Body mass index
Blood urea nitrogenb
Charlson total
Comorbidities
Creatinine
Ejection fraction
Hemoglobin
Adherence type
SCHFI self-care management
Total medications
Consistency, %
Prescribed doses taken, %
Trouble breathing or ankle
swelling within past month
General health perception
Health compared to a year ago

$74 vs ,74
#34 vs .34

41 (18.8)
123 (56.4)

0.029
0.017

2.15
2.01

1.08–4.29
1.13–3.57

$41 vs ,41
$21 vs ,21 or missing
$3 vs ,3
$2 vs ,2
$0.98 vs ,0.98 or missing
#30 vs .30 or missing
#14.1 vs .14.1 or missing
Poor vs better

27 (12.4)
115 (52.8)
100 (45.9)
161 (73.9)
146 (67.0)
105 (48.2)
149 (68.3)
63 (28.9)
89 (40.8)
71 (32.6)
29 (13.3)
38 (17.4)
94 (43.1)

0.029
0.040
0.006
0.016
0.035
0.026
0.003

,0.001
0.025

2.48
1.81
2.19
2.35
1.95
1.89
2.71
3.47
1.88
3.25
3.61
3.90
1.90

1.10–5.61
1.03–3.17
1.25–3.85
1.18–4.71
1.05–3.62
1.08–3.31
1.40–5.23
1.89–6.39
1.07–3.30
1.80–5.89
1.76–7.40
1.88–8.10
1.09–3.32

24 (11.0)
130 (59.6)

0.002
0.049

4.16
1.79

1.69–10.23
1.00–3.20

41 (18.8)
132 (60.6)
12 (5.5)
36 (16.5)

0.001
0.009
0.034
0.014

3.13
2.21
3.80
3.26

1.56–6.29
1.22–4.01
1.11–13.1
1.27–8.17

Social support
Clinical

Self-care

Symptom

Cognition

NYHA class
Fatigue
PHQ total
TICS score

#92 vs .92 or missingc
$12 vs ,12
#1 vs .1
#44 vs .44
Yes vs no
Poor vs fair to excellent
Much worse now than
a year ago vs not much
worse now than a year ago
IV vs I–III
$6 vs ,6
$12 vs ,12
#29 vs .29

,0.001
0.027
,0.001
0.001

Notes: aOut of 218 patients with some Medication Event Monitoring System data; bthe adaptive classification is equivalent to the standard classification of .20 vs #20;
c
patients with missing SCHFI self care management score were the ones who did not have trouble breathing or ankle swelling.
Abbreviations: OR, odds ratio; CI, confidence interval; ANART, American National Adult Reading Test; NYHA, New York Heart Association; PHQ, Patient Health
Questionnaire; SCHFI, Self-Care of Heart Failure Index; TICS, Telephone Interview for Cognitive Status; vs, versus.

Patient Preference and Adherence 2014:8

submit your manuscript | www.dovepress.com

Dovepress

9

Dovepress

Riegel and Knafl

Table 9 Multiple risk-factor model for hospitalization
Variable type

Variable

Demographic
Social support
Clinical

–
–
Hemoglobin
Ejection fraction
Adherence type
Total medications
NYHA class
–

Self-care
Symptom
Cognition

Risk factor

At-risk group, n (%)a

P-value

OR

95% CI

#14.1 vs .14.1 or missing
#30 vs .30 or missing
Poor vs better

149 (68.3)
105 (48.2)
63 (28.9)
71 (32.6)
41 (18.8)

0.008
0.010

2.74
2.39
3.41
2.71
3.22

1.30–5.80
1.24–4.62
1.74–6.68
1.41–5.20
1.43–7.22

$12 vs ,12
IV vs I–III

,0.001
0.003
0.005

Note: aOut of 218 patients with some Medication Event Monitoring System data.
Abbreviations: OR, odds ratio; CI, confidence interval; NYHA, New York Heart Association; vs, versus.

tests for zero coefficients, and so are similar to multiplecomparison approaches. All standard classifications except
the one for BUN were nonsignificant, but this was equivalent
to the adaptive BUN classification.
Results for the adaptive multiple risk-factor model generated considering the 21 significant risk factors of Table 8
are reported in Table 9. This model had five risk factors:
lower Hgb, lower ejection fraction, poor adherence type,
higher total number of prescribed medications, and NYHA
class IV. The model had two clinical, two self-care, and
one symptom risk factors, and no demographic, social support, or cognition risk factors. The LCV score was 0.56979.
In contrast, the best individual risk-factor model based on
poor MEMS adherence had an LCV score of 0.53527, with
substantial percentage decrease of 6.06%, indicating that the
multiple risk-factor model substantially improved on each
of the individual risk-factor models.
Interactions with poor-adherence type were identified for
three risk factors: poor-adherence type with lower ANART
score (#34, 32 [14.7%] patients), with higher MSPSS score
($54, 59 [27.1%] patients), and with lower LNS score

(#8, 41 [18.8%] patients). The percentage decrease in LCV
score for the model based on the poor-adherence type was
insubstantial at 0.35% for the second of these interactions
(with MSPSS score), but was substantial at 1.35% for the
first and at 1.68% for the third.
The adaptive multiple risk-factor model generated considering these three interactions and the 21 significant risk
factors of Table 8 included the single interaction between the
poor-adherence type and lower LNS score. It also included
the same four nonadherence risk factors from the noninteraction model of Table 9. The LCV score was 0.58318,
which was a substantial improvement on the noninteraction
multiple risk-factor model with percentage decrease in the
LCV score of 2.30%.
The adaptive model considering pair-wise interactions is
described in Table 10 and included seven interactions (and
no noninteraction risk factors):
1. poor-adherence type and lower LNS score
2. higher number of comorbid conditions and higher number
of medications
3. higher BUN and lower percentage PDT

Table 10 Multiple risk-factor interaction model for hospitalization
Interaction term 1

Interaction term 2

OR

95% CI

Risk factor

Variable

Risk factor

At-risk group,
n (%)a

P-value

Variable
Adherence type
Comorbidities
Blood urea
nitrogen
Hemoglobin

Poor vs better

#8 vs .8 or missing
$12 vs ,12
#44 vs .44

32 (14.7)
64 (29.4)
21 (9.6)

,0.001
0.001
0.035

6.40
3.46
4.29

2.30–17.8
1.68–7.11
1.14–16.2

#14.1 vs .14.1
or missing

LNS score
Total medications
Prescribed doses
taken, %
Health compared
to a year ago

89 (40.8)

0.009

2.51

1.26–4.99

Age
Body mass index
Ejection fraction

$74 vs ,74
$41 vs ,41 or missing
#30 vs .30 or missing

TICS score
Hemoglobin
Fatigue

Much worse now
than a year ago vs
not much worse
now than a year ago
#29 vs .29
#14.1 vs .14.1 or missing
$6 vs ,6

11 (5.0)
23 (10.6)
62 (28.4)

0.008
0.003
0.008

11.70
5.08
2.80

1.92–71.7
1.77–14.6
1.31–5.96

$2 vs ,2
$21 vs ,21

Note: aOut of 218 patients with some Medication Event Monitoring System data.
Abbreviations: OR, odds ratio; CI, confidence interval; LNS, Letter–Number Sequencing; TICS, Telephone Interview for Cognitive Status; vs, versus.
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4. lower Hgb and much worse perceived health now compared to last year
5. older age and lower TICS score
6. higher BMI and lower Hgb
7. lower ejection fraction and higher fatigue.
The C-index for this model was 0.83 (values between 0.8 to
0.9 are considered to provide excellent discrimination39).
To assess the possibility of collinearity between these
seven interactions, we computed logistic regression models
predicting each of these seven interactions as a function of the
other six. The largest Nagelkerke R2 value for these models
was 9.5%, indicating that collinearity was not a problem for
the seven-interaction model.
Patients had zero to five of these risk factors. Of the 62,
63, 59, 19, eleven, and four patients with zero to five of these
interaction risk factors, respectively, the percentage hospitalized was 9.7%, 19.1%, 54.2%, 79.0%, 90.9%, and 100%.
The hospitalization risk index model based on the count
of the number of these risk factors as the only predictor of
hospitalization had an LCV score of 0.61594, which provided
a substantial improvement over the seven-interaction model,
with percentage decrease in the LCV score of 1.18%. This
model has a C-index of 0.82. As an example, using a cutoff
of 0.5 for generating predictions (ie, predictions based on
maximum likelihood), the sensitivity is 77.2% and the specificity 77.0%, and so well balanced.

Discussion
In this prospective study, we confirmed that both a poor
type of medication adherence pattern and a low percentage
of prescribed doses taken were important predictors of hospitalization in adults with HF. In addition, we identified low
Hgb, depressed ejection fraction, NYHA class IV, and taking
12 or more medications daily as risk factors for hospitalization. When interactions were considered, seven combinations
of factors increased the predictive capability of the model:
1) poor-adherence type and lower score on a test of shortterm memory, 2) higher number of comorbid conditions and
higher number of daily medications, 3) poor kidney function
(higher BUN) and lower percentage prescribed doses taken,
4) lower Hgb and perceptions of poor health, 5) older age
and lower score on the TICS, 6) higher BMI and lower Hgb,
and 7) lower ejection fraction and higher fatigue. Patients
with none of these seven interactions were unlikely to be
hospitalized, but all of those with five of the seven interaction risk factors were hospitalized over the 6-month period.
A pattern of poor medication adherence and taking a
low percentage of prescribed doses were both associated
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with hospitalization in this sample. These results are consistent with prior research,13,14,40,41 but those studies measured
adherence using administrative claims data or retrospective
review of hospital records, so the pattern of adherence and the
percentage of doses taken could only be inferred. What this
study adds is the prospective analysis of individual patterns of
medication-taking behavior in relation to hospitalization.
An important factor interacting with a poor medicationadherence type was impaired cognition. Cognitive deficits
occur in a significant proportion of adults with chronic HF,42
including deficits in memory.43 Prospective memory has
been demonstrated to be related to medication adherence.44
Although short-term memory as measured by the LNS and
prospective memory are related, prospective memory is
more encompassing, referring specifically to the ability to
remember to do something in the future.44 As taking medication on a schedule requires that patients remember to do
so, this result suggests that HF patients who have not compensated for poor memory with a strategy to assist them to
remember medications are at increased risk of hospitalization.
One physiologic factor known to be associated with impaired
cognition is poor kidney function.45 In this study, higher BUN
levels interacted with taking a lower percentage of prescribed
medication doses to predict hospitalization. A memory device
to facilitate adherence may be particularly important in HF
patients with impaired kidney function.
We found that patients taking multiple daily medications
were likely to be hospitalized, perhaps because they were not
taking their medications as prescribed.46 This was especially
true in patients with more comorbid illnesses, where the
number of medications and comorbid illnesses interacted to
predict hospitalizations. This result is not surprising, considering the profile of those individuals with multiple chronic
conditions who are taking numerous medications. Illness
symptoms and medication side effects can be expected to
make routine medication adherence challenging.47
Low Hgb, low ejection fraction, and poor functional
status all predicted hospitalization. Previous investigators
have identified a wide variety of clinical factors associated
with hospitalization, including anemia.48 Although correction of anemia has been shown to slow the progression of
HF and reduce hospitalization rates,49 more than one-third
of the participants in our study were anemic using the World
Health Organization definitions of ,13% for men and ,12%
for women. Correction of anemia with subcutaneous erythropoietin is advocated in clinical guidelines and covered
in the US by Medicare,50 but expense still may be limiting
its widespread use. Low Hgb interacted with self-reported
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perceptions of poor health, suggesting that those patients
who were anemic were symptomatic enough to label themselves as getting worse over time. Low Hgb also interacted
with high BMI, as might be expected for two conditions
that cause high output failure. Depressed ejection fraction
and poor NYHA functional class were both independently
associated with hospitalization, as has been shown by other
investigators.2
Limitations of this study include the relatively small
sample size, compared to epidemiologic studies conducted
with thousands of respondents, collected from a single region
in the US. Participants were younger and better educated than
other community samples. Strengths include the prospective
design, the objective measurement of medication adherence,
and the sophisticated statistical approach that accounted for
general nonlinear adherence trajectories rather than simply
categorizing adherence using the .80% cutoff in percentage PDT used by most prior investigators. This nuanced
approach to understanding medication-adherence patterns
provides important insights into patient behavior that cannot
be discerned from epidemiologic research.
Future research is needed to identify predictors of nonadherence. The World Health Organization adherence model
suggests that socioeconomic, condition, therapy, patient, and
health care-system dimensions contribute to nonadherence,51
and further research is needed to explore these dimensions.
Efforts to identify the strategies used by HF patients to
remember medications is needed. Finally, it will be important
to include cost in future studies, because Sokol et al40 demonstrated that although nonadherence was associated with higher
hospitalization risk in HF patients, there were no differences
in costs compared to those who were more adherent.
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